236 related articles for article (PubMed ID: 37208559)
1. Genetically instrumented LDL-cholesterol lowering and multiple disease outcomes: A Mendelian randomization phenome-wide association study in the UK Biobank.
Pham K; Mulugeta A; Lumsden A; Hyppӧnen E
Br J Clin Pharmacol; 2023 Oct; 89(10):2992-3004. PubMed ID: 37208559
[TBL] [Abstract][Full Text] [Related]
2. Genetically-predicted life-long lowering of low-density lipoprotein cholesterol is associated with decreased frailty: A Mendelian randomization study in UK biobank.
Wang Q; Wang Y; Lehto K; Pedersen NL; Williams DM; Hägg S
EBioMedicine; 2019 Jul; 45():487-494. PubMed ID: 31300347
[TBL] [Abstract][Full Text] [Related]
3. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
[TBL] [Abstract][Full Text] [Related]
4. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
Fang S; Yarmolinsky J; Gill D; Bull CJ; Perks CM; ; Davey Smith G; Gaunt TR; Richardson TG
PLoS Med; 2023 Jan; 20(1):e1003988. PubMed ID: 36595504
[TBL] [Abstract][Full Text] [Related]
5. Causal effects of circulating lipids and lipid-lowering drugs on the risk of epilepsy: a two-sample Mendelian randomization study.
Liang Z; Zhao L; Lou Y; Liu S
QJM; 2023 Jun; 116(6):421-428. PubMed ID: 36964718
[TBL] [Abstract][Full Text] [Related]
6. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.
He JY; Zhang X; Wang K; Lv WQ
J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717
[TBL] [Abstract][Full Text] [Related]
7. Association of lipid-lowering drugs with osteoarthritis outcomes from a drug-target Mendelian randomization study.
Ma W; Chen H; Zhang Z; Xiong Y
PLoS One; 2024; 19(2):e0293960. PubMed ID: 38416763
[TBL] [Abstract][Full Text] [Related]
8. Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study.
Tan Z; Hong J; Sun A; Ding M; Shen J
Front Endocrinol (Lausanne); 2023; 14():1301163. PubMed ID: 38107516
[TBL] [Abstract][Full Text] [Related]
9. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z
Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363
[TBL] [Abstract][Full Text] [Related]
10. A data-driven approach for studying the role of body mass in multiple diseases: a phenome-wide registry-based case-control study in the UK Biobank.
Hyppönen E; Mulugeta A; Zhou A; Santhanakrishnan VK
Lancet Digit Health; 2019 Jul; 1(3):e116-e126. PubMed ID: 33323262
[TBL] [Abstract][Full Text] [Related]
11. Associations of Lipids and Lipid-Lowering Drugs with Risk of Vascular Dementia: A Mendelian Randomization Study.
Zhang X; Geng T; Li N; Wu L; Wang Y; Zheng D; Guo B; Wang B
Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615727
[TBL] [Abstract][Full Text] [Related]
12. The Causal Effects of Blood Iron and Copper on Lipid Metabolism Diseases: Evidence from Phenome-Wide Mendelian Randomization Study.
Zhou J; Liu C; Francis M; Sun Y; Ryu MS; Grider A; Ye K
Nutrients; 2020 Oct; 12(10):. PubMed ID: 33080795
[TBL] [Abstract][Full Text] [Related]
13. Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study.
Qiao L; Lv S; Meng K; Yang J
Clin Rheumatol; 2024 Mar; 43(3):939-947. PubMed ID: 38198113
[TBL] [Abstract][Full Text] [Related]
14. Common and Rare
Hsu LA; Teng MS; Wu S; Chou HH; Ko YL
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142332
[TBL] [Abstract][Full Text] [Related]
15. Association between habitual coffee consumption and multiple disease outcomes: A Mendelian randomisation phenome-wide association study in the UK Biobank.
Nicolopoulos K; Mulugeta A; Zhou A; Hyppönen E
Clin Nutr; 2020 Nov; 39(11):3467-3476. PubMed ID: 32284183
[TBL] [Abstract][Full Text] [Related]
16. Lipid traits and type 2 diabetes risk in African ancestry individuals: A Mendelian Randomization study.
Soremekun O; Karhunen V; He Y; Rajasundaram S; Liu B; Gkatzionis A; Soremekun C; Udosen B; Musa H; Silva S; Kintu C; Mayanja R; Nakabuye M; Machipisa T; Mason A; Vujkovic M; Zuber V; Soliman M; Mugisha J; Nash O; Kaleebu P; Nyirenda M; Chikowore T; Nitsch D; Burgess S; Gill D; Fatumo S
EBioMedicine; 2022 Apr; 78():103953. PubMed ID: 35325778
[TBL] [Abstract][Full Text] [Related]
17. Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis.
Harrison SC; Holmes MV; Burgess S; Asselbergs FW; Jones GT; Baas AF; van 't Hof FN; de Bakker PIW; Blankensteijn JD; Powell JT; Saratzis A; de Borst GJ; Swerdlow DI; van der Graaf Y; van Rij AM; Carey DJ; Elmore JR; Tromp G; Kuivaniemi H; Sayers RD; Samani NJ; Bown MJ; Humphries SE
JAMA Cardiol; 2018 Jan; 3(1):26-33. PubMed ID: 29188294
[TBL] [Abstract][Full Text] [Related]
18. Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study.
Zhao SS; Yiu ZZN; Barton A; Bowes J
JAMA Dermatol; 2023 Mar; 159(3):275-280. PubMed ID: 36696131
[TBL] [Abstract][Full Text] [Related]
19. Associations between lipid-lowering drugs and pregnancy and perinatal outcomes: a Mendelian randomization study.
Wang R; Zhao J; Li L; Huo Y
J Hypertens; 2024 Apr; 42(4):727-734. PubMed ID: 38230624
[TBL] [Abstract][Full Text] [Related]
20. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study.
Huang W; Xiao J; Ji J; Chen L
Elife; 2021 Dec; 10():. PubMed ID: 34866576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
